The effect of peptide receptor radionuclide therapy (PRRT) on symptoms and tumour burden in patients with metastatic neuroendocrine tumour (NET)

2016 ◽  
Author(s):  
Stalin Abraham ◽  
Ruth Casey ◽  
Ben Challis ◽  
Deborah Pitfield ◽  
S Whitley ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Neuroendocrine Tumour ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumour Burden ◽  
Peptide Receptor ◽  
Metastatic Neuroendocrine Tumour

scholarly journals Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0260073
Author(s):  
Daphne M. V. de Vries–Huizing ◽  
Michelle W. J. Versleijen ◽  
Michiel Sinaasappel ◽  
Iris Walraven ◽  
Martine M. Geluk–Jonker ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Selection Criteria ◽  
Progressive Disease ◽  
Neuroendocrine Tumour ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumour Volume ◽  
Clinical Impact ◽  
Peptide Receptor ◽  
Grade 3

Background Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this study was to evaluate the haematotoxicity course during PRRT and to compare baseline parameters between haematotoxicity grades. Methods In this retrospective study, 100 patients with a neuroendocrine tumour treated with PRRT were included. Patients were treated with an aimed number of four cycles with 7.4 GBq [177Lu]Lu-DOTA-TATE administered every 10 weeks. Haematological assessment was performed at baseline and frequently up to 10 weeks after the fourth cycle. The lowest haematological value was graded according to CTCAE v5.0, and patients were classified using the highest observed grade. Differences in baseline parameters, including [68Ga]Ga-DOTA-TATE positive tumour volume, were evaluated between CTCAE grades. Results Four cycles were completed by 86/100 of patients, 4/100 patients discontinued due to haematotoxicity, and 10/100 patients due to progressive disease. The treatment course was adjusted due to haematotoxicity in 24/100 patients, including postponed next cycle (n = 17), reduced administered activity (n = 13), and both adjustments (n = 10). The most observed haematotoxicity grade was grade 0–1 in 54/100 patients, grade 2 in 38/100 and grade 3–4 in 8/100. Significant differences in baseline leucocyte, neutrophil and platelet counts were observed between grade 0–1 and grade 2. However, the correlation between baseline and lowest observed values was poor to moderate. No differences between haematotoxicity grades and baseline parameters or somatostatin receptor positive tumour volume was observed. Conclusions The incidence of severe haematotoxicity was low with extensive screening and monitoring. The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment. Baseline parameters showed limited correlation with the degree of decline in haematological values.

Neoadjuvant90Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report

2014 ◽  
Vol 87 (1-2) ◽  
pp. 92-93 ◽  
Author(s):  
Jennifer Ryan ◽  
Timothy Akhurst ◽  
A. Craig Lynch ◽  
Michael Michael ◽  
Alexander G. Heriot
Keyword(s):  
Case Report ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumour ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

Effects of Music on the Psyche of Neuroendocrine Tumour Patients Undergoing Peptide Receptor Radionuclide Therapy

2012 ◽  
pp. 853-864
Author(s):  
Remigius Orjiukwu ◽  
Margot Staudinger ◽  
Daniel Putzer ◽  
Dietmar Waitz ◽  
Michael Gabriel ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Neuroendocrine Tumour ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour

2018 ◽  
Vol 2018 ◽  
Author(s):  
Tiago Nunes da Silva ◽  
M L F van Velthuysen ◽  
Casper H J van Eijck ◽  
Jaap J Teunissen ◽  
J Hofland ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Radiation Effects ◽  
Neuroendocrine Tumour ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
List Type ◽  
Symptomatic Disease ◽  
Peptide Receptor ◽  
Pancreatic Net ◽  
Tumour Reduction

Summary Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (metastatic) disease limiting the possibility of surgical cure. Several treatment options have been used in experimental neoadjuvant settings to improve the outcomes in such cases. Peptide receptor radionuclide therapy (PPRT) using beta emitting radiolabelled somatostatin analogues has been used in progressive pancreatic NETs. We report a 55-year-old female patient with a 12.8 cm pancreatic NET with significant local stomach and superior mesenteric vein compression and liver metastases. The patient underwent treatment with [177Lutetium-DOTA0,Tyr3]octreotate (177Lu-octreotate) for the treatment of local and metastatic symptomatic disease. Six months after 4 cycles of 177lutetium-octreotate, resolution of the abdominal complaints was associated with a significant reduction in tumour size and the tumour was rendered operable. Histology of the tumour showed a 90% necrotic tumour with abundant hyalinized fibrosis and haemorrhage compatible with PPRT-induced radiation effects on tumour cells. This report supports that PPRT has a role in unresectable and metastatic pancreatic NET. Learning points: PRRT with 177Lu-octreotate can be considered a useful therapy for symptomatic somatostatin receptor-positive pancreatic NET. The clinical benefits of PRRT with 177Lu-octreotate can be seen in the first months while tumour reduction can be seen up to a year after treatment. PRRT with 177Lu-octreotate was clinically well tolerated and did not interfere with the subsequent surgical procedure. PRRT with 177Lu-octreotate can result in significant tumour reduction and may improve surgical outcomes. As such, this therapy can be considered as a neoadjuvant therapy.

Sign in / Sign up

Export Citation Format

Share Document